Literature DB >> 22382343

Epidemiology of systemic sclerosis in a large US managed care population.

Daniel E Furst1, Ancilla W Fernandes, Serban R Iorga, Warren Greth, Tim Bancroft.   

Abstract

OBJECTIVE: To estimate the incidence and prevalence of systemic sclerosis (SSc) in a large US managed care organization (MCO) database.
METHODS: Subjects with claims-based evidence of SSc (ICD-9-CM code 710.1x) were identified from a health plan database. Incidence and prevalence for the period 2003-2008 were calculated.
RESULTS: The overall age- and sex-adjusted incidence rate (2003-2008) for SSc was 5.6 cases per 100,000 person-years. The annual prevalence of SSc ranged from 13.5 in 2003 to 18.4 (per 100,000) in 2008.
CONCLUSION: This analysis suggests a higher incidence and lower prevalence of SSc in this MCO than those previously reported for the United States.

Entities:  

Mesh:

Year:  2012        PMID: 22382343     DOI: 10.3899/jrheum.111106

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010.

Authors:  P Elfving; O Marjoniemi; H Niinisalo; A Kononoff; L Arstila; E Savolainen; J Rutanen; O Kaipiainen-Seppänen
Journal:  Rheumatol Int       Date:  2016-04-06       Impact factor: 2.631

Review 2.  Systemic sclerosis-associated fibrosis: an accelerated aging phenotype?

Authors:  Tracy R Luckhardt; Victor J Thannickal
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

3.  Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts.

Authors:  Anne E Wyman; Zahid Noor; Rita Fishelevich; Virginia Lockatell; Nirav G Shah; Nevins W Todd; Sergei P Atamas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-04-06       Impact factor: 5.464

4.  Rheumatologic diseases in patients with inborn errors of immunity in the USIDNET registry.

Authors:  N Padem; H Wright; R Fuleihan; E Garabedian; D Suez; C Cunningham-Rundles; R A Marsh; A Khojah
Journal:  Clin Rheumatol       Date:  2022-01-31       Impact factor: 2.980

5.  Epidemiology and Trends in Survival of Systemic Sclerosis in Olmsted County (1980-2018): A Population-based Study.

Authors:  Caitrin M Coffey; Yasser A Radwan; Avneek S Sandhu; Cynthia S Crowson; Philippe R Bauer; Eric L Matteson; Ashima Makol
Journal:  J Scleroderma Relat Disord       Date:  2021-06-23

Review 6.  Sirtuins and Accelerated Aging in Scleroderma.

Authors:  Anne E Wyman; Sergei P Atamas
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

7.  Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis.

Authors:  Ann-Christin Pecher; Felix Kettemann; Elisa Asteriti; Hannes Schmid; Silke Duerr-Stoerzer; Hildegard Keppeler; Joerg Christoph Henes; Reinhild Klein; Clemens Hinterleitner; Kathy-Ann Secker; Corina Schneidawind; Lothar Kanz; Dominik Schneidawind
Journal:  Arthritis Res Ther       Date:  2019-10-15       Impact factor: 5.156

8.  Dental management of scleroderma patients using pentoxifylline plus vitamin E with and without TheraBite® to reduce trismus: Two case reports and brief review of literature.

Authors:  Daniel N Reed; David L Hall; James H Cottle; Katherine Frimenko; Christina K Horton; Farah Abu Sharkh; Rachel Beckett; Brandon Hernandez; Hannah Mabe; Shadee T Mansour; Sebastian A Rodriguez; Bradley Weprin; Leigh E Yarborough
Journal:  Clin Case Rep       Date:  2020-01-17

9.  Scleroderma-related interstitial lung disease.

Authors:  Sally Suliman; Abdalhamid Al Harash; William Neil Roberts; Rafael L Perez; Jesse Roman
Journal:  Respir Med Case Rep       Date:  2017-07-15

10.  Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.

Authors:  Qiang Li; Laura Wallace; Padmaja Patnaik; Margarida Alves; Martina Gahlemann; Veronika Kohlbrenner; Christina Raabe; Jocelyn R Wang; Elizabeth M Garry
Journal:  Rheumatology (Oxford)       Date:  2021-04-06       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.